Figure 2  .

Kaplan-Meier estimates of the cumulative proportion of eyes treated with verteporfin or given placebo with moderate visual acuity loss (⩾15 letters or approximately ⩾3 lines) at each 3 month study visit over time during the first 12 months of the TAP investigation. (Reproduced with permission from Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation in age related macular degeneration with verteporfin. Arch Ophthalmol 1999;117:1329-45.)